Affiliations: Neurochemistry Laboratory, Massachusetts General Hospital (East), and Harvard Medical School, Charlestown, MA, USA
Correspondence:
[*]
Correspondence to: Jack T. Rogers, Neurochemistry Laboratory, Massachusetts General Hospital (East), and Harvard Medical School, 149, 13th Street, Charlestown, MA 02129, USA. E-mail: [email protected].
Abstract: Familial Alzheimer’s disease (fAD) mutations in the amyloid-β protein precursor (AβPP) enhance brain AβPP C-Terminal Fragment (CTF) levels to inhibit lysosomal v-ATPase. Consequent disrupted acidification of the endolysosomal pathway may trigger brain iron deficiencies and mitochondrial dysfunction. The iron responsive element (IRE) in the 5’Untranslated-region of AβPP mRNA should be factored into this cycle where reduced bioavailable Fe-II would decrease IRE-dependent AβPP translation and levels of APP-CTFβ in a cycle to adaptively restore iron homeostasis while increases of transferrin-receptors is evident. In healthy younger individuals, Fe-dependent translational modulation of AβPP is part of the neuroprotective function of sAβPPα with its role in iron transport.
Keywords: Alzheimer’s disease, amyloid-β protein precursor, C-terminal
fragments, iron, iron homeostasis, iron responsive element, iron regulatory protein, lysosomes, 5’Untranslated region
